Phase 3 trial of reproxalap for dry eye disease treatment underway
Click Here to Manage Email Alerts
The first patient has been enrolled in the phase 3 TRANQUILITY trial evaluating reproxalap for the treatment of patients with dry eye disease, according to a press release from Aldeyra Therapeutics.
The multicenter randomized, double-masked, parallel-design, vehicle-controlled clinical trial is designed to assess the safety and efficacy of reproxalap ophthalmic solution 0.25% vs. vehicle based on objective sign endpoints of dry eye. The analysis will include tear reactive aldehyde species (RASP) levels, Schirmer test and conjunctival redness. Results from a run-in cohort of 20 patients are expected this year and will be used to power the main cohort of the trial.
“Initiation of the phase 3 TRANQUILITY trial, the first trial designed to characterize the acute effects of reproxalap on RASP and other objective signs of dry eye disease, marks another important step toward a planned NDA submission in dry eye disease by the end of 2021,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release.
Read more about
Click Here to Manage Email Alerts